Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition
- 15 June 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (12) , 5374-5379
- https://doi.org/10.1158/0008-5472.can-04-3379
Abstract
Previous experiments with PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, using irradiated human FaDu squamous cell carcinoma in nude mice, suggested that radiation-damaged tumor vessels are more sensitive to VEGFR inhibition. To test this hypothesis, the tumor transplantation site (i.e., the right hind leg of nude mice) was irradiated 10 days before transplantation of FaDu to induce radiation damage in the host tissue. FaDu tumors vascularized by radiation-damaged blood vessels appeared later, grew at a slower rate, and showed more necrosis and a smaller vessel area per central tumor section than controls. PTK787/ZK222584 at a daily dose of 50 mg/kg body weight had no impact on growth of control tumors. In contrast, tumors vascularized by radiation-damaged vessels responded to PTK787/ZK222584 with longer latency and slower growth rate than controls, and a trend toward further increase in necrosis, indicating that irradiated tumor vessels are more susceptible to VEGFR inhibition than unirradiated vessels. Although not proving causality, expression analysis of VEGF and VEGFR2 shows that enhanced sensitivity of irradiated vessels to a specific inhibitor of VEGFR tyrosine kinases correlates with increased expression of the molecular target.Keywords
This publication has 26 references indexed in Scilit:
- Pathophysiological Effects of Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody plus Fractionated Radiotherapy on Murine Mammary TumorsCancer Research, 2004
- Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in TumorsCancer Research, 2004
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584Seminars in Oncology, 2003
- Tumorigenesis and the angiogenic switchNature Reviews Cancer, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Tumor angiogenesis and accessibility: Role of vascular endothelial growth factorSeminars in Oncology, 2002
- Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouseInternational Journal of Radiation Biology, 2001
- Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawalJournal of Clinical Investigation, 1999
- Ultrastructural Studies on Tumor Capillaries of a Rat Rhabdomyosarcoma during Fractionated RadiotherapyCells Tissues Organs, 1994
- Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues.Journal of Clinical Investigation, 1992